Skip to content
Screener

Mineralys Therapeutics, Inc. MLYS Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$730K-39.9%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC
-$162K-118%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$2.22M-49.3%

Other financials

Income statement

See full
Operating income-$45.3M-2.0%
Net income-$39.3M+6.8%
EPS (diluted)-$0.47+40.5%

Balance sheet

See full
Cash & equivalents$1.2M-14.6%
Total equity$638.1M+86.8%
Total assets$652.9M+83.9%

Cash flow

See full
Operating cash flow-$39.5M+13.2%
CapEx$15.0K
Free cash flow-$37.9M+43.3%

Valuation

See full
Market cap$2.41B+185%

Returns & leverage

See full
Return on equity-31%-9.6pp
Current ratio44.3×+17.8×

Where this comes from

Reported directly by Mineralys Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001933414-26-000084
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Net loss$(39,339)$(42,211)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation6,5483,645
Accretion of discount on held-to-maturity securities(4,625)(1,046)
Depreciation and amortization615
Changes in operating assets and liabilities:
Accrued interest receivable28952
Prepaid, other current assets, and other assets(1,948)(4,396)

Item 1. Financial Statements

FAQ

What is Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Mineralys Therapeutics, Inc. (MLYS) reported accretion (amortization) of discounts and premiums, investments of $4.63M in Q1 2026.
How has Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments increased by 342.2% year-over-year, from $1.05M to $4.63M.
What is the long-term trend for Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 147.8% compound annual growth rate (CAGR), from $649K to $9.88M.
What does accretion (amortization) of discounts and premiums, investments mean?
This represents the non-cash adjustment to net income resulting from the amortization of premiums or the accretion of discounts on held-to-maturity or available-for-sale investment securities. It reflects the gradual recognition of interest income over the life of the investment to align the carrying value with the effective interest rate. Investors use this to reconcile reported net income with actual cash flows generated from investment portfolios.

Ask your AI about Mineralys Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude